S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$5.73
-0.17 (-2.88%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.31
$8.93
50-Day Range
$4.46
$7.31
52-Week Range
$1.05
$11.59
Volume
8.02 million shs
Average Volume
1.72 million shs
Market Capitalization
$342.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.29

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
79.5% Upside
$10.29 Price Target
Short Interest
Bearish
7.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Avadel Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.86) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

914th out of 1,072 stocks

Pharmaceutical Preparations Industry

454th out of 534 stocks

AVDL stock logo

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

What 5 Analyst Ratings Have To Say About Avadel Pharmaceuticals
Avadel Pharmaceuticals Provides Corporate Update
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings
8/09/2022
Today
10/06/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
Employees
66
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$10.29
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+79.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-77,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.33 million
Book Value
$1.33 per share

Miscellaneous

Free Float
57,880,000
Market Cap
$342.61 million
Optionable
Optionable
Beta
1.43

Social Links


Key Executives

  • Mr. Gregory J. Divis Jr. (Age 55)
    CEO & Director
    Comp: $862.59k
  • Mr. Thomas S. McHugh (Age 57)
    Sr. VP & CFO
    Comp: $550k
  • Mr. Richard Kim (Age 53)
    Chief Commercial Officer
    Comp: $596.3k
  • Mr. Jerad G. Seurer
    Gen. Counsel & Company Sec.
  • Mr. Gregory J. Davis (Age 57)
    VP of Corp. and Bus. Devel.
  • Mr. Mark W. Elrod
    VP of Sales
  • Ms. Angie Woods
    VP of People & Culture
  • Mr. Christian Kalita Pharm.D
    Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
  • Mr. Steven G. Sullivan (Age 57)
    VP of Sales & Marketing and Head of Commercial Operations
  • Dr. Jordan S. Dubow M.D. (Age 44)
    Consultant













AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price forecast for 2022?

6 equities research analysts have issued 12 month price targets for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they anticipate the company's stock price to reach $10.29 in the next year. This suggests a possible upside of 79.5% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2022?

Avadel Pharmaceuticals' stock was trading at $8.08 at the beginning of the year. Since then, AVDL stock has decreased by 29.1% and is now trading at $5.73.
View the best growth stocks for 2022 here
.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its earnings results on Tuesday, August, 9th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.60. During the same quarter in the prior year, the company earned ($0.33) earnings per share.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $5.73.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $342.61 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.